Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NSC-CRAd-Survivin-pk7 |
| Synonyms | |
| Therapy Description |
NSC-CRAd-Survivin-pk7 is a virotherapy comprised of an oncolytic virus driven by the survivin promoter and delivered via allogeneic neural stem cells, potentially resulting in reduced tumor burden and a cytotoxic effect in tumor cells expressing survivin (PMID: 30719498). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NSC-CRAd-Survivin-pk7 | NSC-CRAd-Survivin-pk7 is a virotherapy comprised of an oncolytic virus driven by the survivin promoter and delivered via allogeneic neural stem cells, potentially resulting in reduced tumor burden and a cytotoxic effect in tumor cells expressing survivin (PMID: 30719498). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03072134 | Phase I | NSC-CRAd-Survivin-pk7 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | Completed | USA | 0 |